Quality-of-life in lung cancer varies, with certain treatments leading to sleep-related issues, pain, and emotional changes depending on disease stage.

Immunotherapy shows promise in reducing recurrence rates for high-risk skin cancer, despite mixed results in recent clinical ...

Non-small cell lung cancer (NSCLC) develops in lung tissues, but when it's metastatic, it has spread to distant areas of the ...

Panelists discuss how the PODIUM-303 study demonstrated improved progression-free survival (9.3 vs 7.4 months) and response rates (56% vs 44%) when adding retifanlimab to carboplatin-paclitaxel in ...

Non-Small Cell Lung Cancer Market grows as immunotherapy approvals by Merck & Bristol-Myers reshape global treatment pathways. Anurag Tiwari Orion Market Research Pvt Ltd +91 91798 28694 email us here ...

Survival for non-small-cell lung cancer (NSCLC) remains unacceptably low, even in stage IA–IIA. Current guidelines recommend adjuvant treatment for patients considered to be at high risk in stages IB ...

Moreover, using Illumina methylation BeadChip data from public datasets and a local cohort, we developed a DNA methylation-based classifier utilizing the CatBoost algorithm to identify four common ...

C5aR1 has previously been found to be upregulated in several inflammatory and infectious diseases, as well as in cancer types like non-small cell lung cancer and gastric cancer.

n Ibrilatazar’s Phase I/IIa ENDOLUNG clinical trial was recently published in the prestigious scientific journal Lung Cancer. n The trial evaluated the safety and efficacy of ibrilatazar (ABTL0812) ...

Traws Pharma published key clinical efficacy data for rigosertib in patients with RDEB-associated squamous cell carcinoma. What is rigosertib being evaluated for?

Regeneron Pharmaceuticals announced promising results from the Phase 3 C-POST trial of Libtayo (cemiplimab), a PD-1 inhibitor for patients with high-risk cutaneous squamous cell carcinoma (CSCC ...

e20586Background: Squamous cell lung carcinoma (sqNSCLC) accounts for 25-30% of all non-small cell lung cancer (NSCLC) cases and is associated with poor prognosis. Although the addition of anti-PD(L)1 ...